Treatment of melanoma with a serotype 5/3 chimeric oncolytic adenovirus coding for GM-CSF: Results in vitro, in rodents and in humans

International Journal of Cancer

Volumn 137, Issue 7, 2015, Pages 1775-1783

  Bramante, Simona ^a   Kaufmann, Johanna K ^b   Veckman, Ville ^c   Liikanen, Ilkka ^a   Nettelbeck, Dirk M ^b   Hemminki, Otto ^a   Vassilev, Lotta ^d   Cerullo, Vincenzo ^a,e   Oksanen, Minna ^a   Heiskanen, Raita ^d   Joensuu, Timo ^f   Kanerva, Anna ^a,g   Pesonen, Sari ^a   Matikainen, Sampsa ^c   Vähä Koskela, Markus ^a   Koski, Anniina ^a   Hemminki, Akseli ^a,h,i  

^a UNIVERSITY OF HELSINKI   (Finland)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c FINNISH INSTITUTE OF OCCUPATIONAL HEALTH   (Finland)

^d Oncos Therapeutics   (Finland)

^e UNIVERSITY OF HELSINKI   (Finland)

^f Docrates Oncology Clinic   (Finland)

^g HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^h TILT Biotherapeutics Ltd   (Finland)

ⁱ Cambridge Discovery Park   (United States)

Author keywords

combination treatment; cyclophosphamide; GM CSF; immunotherapy; melanoma; oncolytic adenovirus

Indexed keywords

CYCLOPHOSPHAMIDE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; NEUTRALIZING ANTIBODY; ONCOLYTIC ADENOVIRUS;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DIFFERENTIATION; CLINICAL ARTICLE; CONTROLLED STUDY; DIZZINESS; DRUG SAFETY; EDEMA; FATIGUE; FEMALE; FEVER; HAMSTER; HUMAN; HUMAN ADENOVIRUS 5; HUMAN CELL; IN VITRO STUDY; LOW DRUG DOSE; LYMPHOCYTE COUNT; MACROPHAGE; MELANOMA; MELANOMA CELL; MONOCYTE; MOUSE; NAUSEA; NONHUMAN; ONCOLYTIC VIROTHERAPY; PAIN; PRIORITY JOURNAL; RIGOR; SIDE EFFECT; TUMOR REGRESSION; TUMOR XENOGRAFT; VIRUS GENOME; VIRUS LOAD; ADENOVIRIDAE; ANIMAL; BIOSYNTHESIS; DRUG SCREENING; GENETICS; NUDE MOUSE; PATHOLOGY; PHYSIOLOGY; PROCEDURES; RANDOMIZATION; TUMOR CELL LINE; VIROLOGY;

ADENOVIRIDAE; ANIMALS; CELL DIFFERENTIATION; CELL LINE, TUMOR; CRICETINAE; CYCLOPHOSPHAMIDE; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; MACROPHAGES; MELANOMA; MICE; MICE, NUDE; MONOCYTES; ONCOLYTIC VIROTHERAPY; RANDOM ALLOCATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84943423634     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29536     Document Type: Article

References (50)

1. Ferlay J, Shin HR, Bray F, et al., Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-917.
2. Korn EL, Liu PY, Lee SJ, et al., Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol 2008; 26: 527-34.
3. Johnson TM, Smith JW, II, Nelson BR, et al., Current therapy for cutaneous melanoma. J Am Acad Dermatol 1995; 32: 689-707.
4. Hodi FS, O'Day SJ, McDermott DF, et al., Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-23.
5. Chapman PB, Hauschild A, Robert C, et al., Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364: 2507-16.
6. Fellner C,. Ipilimumab (yervoy) prolongs survival in advanced melanoma: serious side effects and a hefty price tag may limit its use. Pharm Therap 2012; 37: 503-30.
7. Smith JL, Jr, Stehlin JS, Jr., Spontaneous regression of primary malignant melanomas with regional metastases. Cancer 1965; 18: 1399-415.
8. Lee PP, Yee C, Savage PA, et al., Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med 1999; 5: 677-85.
9. Ladanyi A, Kiss J, Somlai B, et al., Density of DC-LAMP(+) mature dendritic cells in combination with activated T lymphocytes infiltrating primary cutaneous melanoma is a strong independent prognostic factor. Cancer Immunol Immunother CII 2007; 56: 1459-69.
10. Tuve S, Liu Y, Tragoolpua K, et al., In situ adenovirus vaccination engages T effector cells against cancer. Vaccine 2009; 27: 4225-39.
11. Kaufman HL, Andtbacka RHI, Collichio FA, et al., Primary overall survival (OS) from OPTiM, a randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma. J Clin Oncol 2014; 32: 5s. ASCO 2014 (suppl; abstr 9008a).
12. Dranoff G,. GM-CSF-secreting melanoma vaccines. Oncogene 2003; 22: 3188-92.
13. Geissler K, Harrington M, Srivastava C, et al., Effects of recombinant human colony stimulating factors (CSF) (granulocyte-macrophage CSF, granulocyte CSF, and CSF-1) on human monocyte/macrophage differentiation. J Immunol 1989; 143: 140-6.
14. Grabstein KH, Urdal DL, Tushinski RJ, et al., Induction of macrophage tumoricidal activity by granulocyte-macrophage colony-stimulating factor. Science (New York, NY) 1986; 232: 506-8.
15. Koski A, Kangasniemi L, Escutenaire S, et al., Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF. Mol Ther 2010; 18: 1874-84.
16. Kanerva A, Nokisalmi P, Diaconu I, et al., Antiviral and antitumor T-cell immunity in patients treated with GM-CSF-coding oncolytic adenovirus. Clin Cancer Res 2013; 19: 2734-44.
17. Kanerva A, Zinn KR, Chaudhuri TR, et al., Enhanced therapeutic efficacy for ovarian cancer with a serotype 3 receptor-targeted oncolytic adenovirus. Mol Ther 2003; 8: 449-58.
18. Bramante S, Koski A, Kipar A, et al., Serotype chimeric oncolytic adenovirus coding for GM-CSF for treatment of sarcoma in rodents and humans. Int J Cancer 2014; 135: 720-30.
19. Liikanen I, Ahtiainen L, Hirvinen ML, et al., Oncolytic adenovirus with temozolomide induces autophagy and antitumor immune responses in cancer patients. Mol Ther 2013; 21: 1212-23.
20. Kanerva A, Mikheeva GV, Krasnykh V, et al., Targeting adenovirus to the serotype 3 receptor increases gene transfer efficiency to ovarian cancer cells. Clin Cancer Res 2002; 8: 275-80.
21. Dmitriev I, Krasnykh V, Miller CR, et al., An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J Virol 1998; 72: 9706-13.
22. Fleischli C, Sirena D, Lesage G, et al., Species B adenovirus serotypes 3, 7, 11 and 35 share similar binding sites on the membrane cofactor protein cd46 receptor. J Gen Virol 2007; 88: 2925-34.
23. Nettelbeck DM, Rivera AA, Kupsch J, et al., Retargeting of adenoviral infection to melanoma: combining genetic ablation of native tropism with a recombinant bispecific single-chain diabody (scDb) adapter that binds to fiber knob and HMWMAA. Int J Cancer 2004; 108: 136-45.
24. Diaconu I, Cerullo V, Escutenaire S, et al., Human adenovirus replication in immunocompetent syrian hamsters can be attenuated with chlorpromazine or cidofovir. J Gene Med 2010; 12: 435-45.
25. Pirhonen J, Sareneva T, Kurimoto M, et al., Virus infection activates IL-1 beta and IL-18 production in human macrophages by a caspase-1-dependent pathway. J Immunol 1999; 162: 7322-9.
26. Cerullo V, Pesonen S, Diaconu I, et al., Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients. Cancer Res 2010; 70: 4297-309.
27. Cerullo V, Diaconu I, Kangasniemi L, et al., Immunological effects of low-dose cyclophosphamide in cancer patients treated with oncolytic adenovirus. Mol Ther 2011; 19: 1737-46.
28. Bauerschmitz GJ, Lam JT, Kanerva A, et al., Treatment of ovarian cancer with a tropism modified oncolytic adenovirus. Cancer Res 2002; 62: 1266-70.
29. Young DA, Lowe LD, Clark SC,. Comparison of the effects of IL-3, granulocyte-macrophage colony-stimulating factor, and macrophage colony-stimulating factor in supporting monocyte differentiation in culture. Analysis of macrophage antibody-dependent cellular cytotoxicity. J Immunol 1990; 145: 607-15.
30. Lai KC, Chang KW, Liu CJ, et al., IFN-induced protein with tetratricopeptide repeats 2 inhibits migration activity and increases survival of oral squamous cell carcinoma. Mol Cancer Res 2008; 6: 1431-9.
31. Hemminki O, Diaconu I, Cerullo V, et al., Ad3-hTERT-E1A, a fully serotype 3 oncolytic adenovirus, in patients with chemotherapy refractory cancer. Mol Ther 2012; 20: 1821-30.
32. Alemany R, Suzuki K, Curiel DT,. Blood clearance rates of adenovirus type 5 in mice. J Gen Virol 2000; 81: 2605-9.
33. Koski A, Ahtinen H, Liljenback H, et al., [(18)F]-fluorodeoxyglucose positron emission tomography and computed tomography in response evaluation of oncolytic adenovirus treatments of patients with advanced cancer. Hum Gene Ther 2013; 24: 1029-41.
34. Hitt MM, Graham FL,. Adenovirus vectors for human gene therapy. Adv Virus Res 2000; 55: 479-505.
35. Bett AJ, Prevec L, Graham FL,. Packaging capacity and stability of human adenovirus type 5 vectors. J Virol 1993; 67: 5911-21.
36. Kanerva A, Hemminki A,. Modified adenoviruses for cancer gene therapy. Int J Cancer 2004; 110: 475-80.
37. Croy BA, Linder KE, Yager JA,. Primer for non-immunologists on immune-deficient mice and their applications in research. Comp Med 2001; 51: 300-13.
38. Sova P, Ren XW, Ni S, et al., A tumor-targeted and conditionally replicating oncolytic adenovirus vector expressing TRAIL for treatment of liver metastases. Mol Ther 2004; 9: 496-509.
39. Man S, Bocci G, Francia G, et al., Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. Cancer Res 2002; 62: 2731-5.
40. Wang R, Qin S, Chen Y, et al., Enhanced anti-tumor and anti-angiogenic effects of metronomic cyclophosphamide combined with endostar in a xenograft model of human lung cancer. Oncol Rep 2012; 28: 439-45.
41. Loven D, Hasnis E, Bertolini F, et al., Low-dose metronomic chemotherapy: from past experience to new paradigms in the treatment of cancer. Drug Discov Today 2013; 18: 193-201.
42. Cohen AM, Hines DK, Korach ES, et al., In vivo activation of neutrophil function in hamsters by recombinant human granulocyte colony-stimulating factor. Infect Immun 1988; 56: 2861-5.
43. Thomas MA, Spencer JF, La Regina MC, et al., Syrian hamster as a permissive immunocompetent animal model for the study of oncolytic adenovirus vectors. Cancer Res 2006; 66: 1270-6.
44. Zhang JF, Hu C, Geng Y, et al., Treatment of a human breast cancer xenograft with an adenovirus vector containing an interferon gene results in rapid regression due to viral oncolysis and gene therapy. Proc Natl Acad Sci USA 1996; 93: 4513-8.
45. Rosenthal AS, Shevach EM,. Function of macrophages in antigen recognition by guinea pig T lymphocytes. I. Requirement for histocompatible macrophages and lymphocytes. J Exp Med 1973; 138: 1194-212.
46. Serafini P, Carbley R, Noonan KA, et al., High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Res 2004; 64: 6337-43.
47. Hemminki A,. Treatment of chemotherapy-refractory cancer in the advanced therapy access program. Mol Ther 2012; 20: 1654-5.
48. Hemminki A, Oksanen M, Merisalo-Soikkeli M,. Oncolytic virotherapy trials-letter. Clin Cancer Res 2013; 19: 4541-2.
49. Wolchok JD, Kluger H, Callahan MK, et al., Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013; 369: 122-33.
50. Swaika A, Crozier JA, Joseph RW,. Vemurafenib: an evidence-based review of its clinical utility in the treatment of metastatic melanoma. Drug Des Dev Ther 2014; 8: 775-87.